Assignee
CUREVAC AG
DE·83 granted patents·112 pending applications·2,406 citations·filing 2013–2022
Top patents by PatentIndex Score
195 records- 0199US11078247B2RNA encoding a therapeutic proteinCUREVAC AG·Filed 2017·Granted Aug 3, 2021·57 cites·18 claims
- 0299US10738306B2Artificial nucleic acid molecules for improved protein or peptide expressionCUREVAC AG·Filed 2017·Granted Aug 11, 2020·36 cites·20 claims
- 0399US10434158B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Oct 8, 2019·31 cites·21 claims
- 0499US10117920B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Nov 6, 2018·32 cites·12 claims
- 0599US9655955B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted May 23, 2017·42 cites·20 claims
- 0699US9463228B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Oct 11, 2016·28 cites·20 claims
- 0799US9439956B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 13, 2016·29 cites·19 claims
- 0899US9433669B2Application of mRNA for use as a therapeutic against tumor diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0999US9433670B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 1098US11458195B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2019·Granted Oct 4, 2022·12 cites·25 claims
- 1198US11433027B2Dry powder composition comprising long-chain RNACUREVAC AG·Filed 2020·Granted Sep 6, 2022·15 cites·25 claims
- 1298US11369694B2Rabies vaccineCUREVAC AG·Filed 2020·Granted Jun 28, 2022·11 cites·20 claims
- 1398US11345920B2Artificial nucleic acid molecules for improved protein expressionCUREVAC AG·Filed 2021·Granted May 31, 2022·17 cites·28 claims
- 1498US11286492B2Artificial nucleic acid molecules for improved protein expressionCUREVAC AG·Filed 2021·Granted Mar 29, 2022·22 cites·30 claims
- 1598US11266735B2Combination vaccineCUREVAC AG·Filed 2020·Granted Mar 8, 2022·40 cites·17 claims
- 1698US11254951B2Artificial nucleic acid moleculesCUREVAC AG·Filed 2018·Granted Feb 22, 2022·28 cites·20 claims
- 1798US11179337B2Dry powder composition comprising long-chain RNACUREVAC AG·Filed 2019·Granted Nov 23, 2021·35 cites·28 claims
- 1898US11135312B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2014·Granted Oct 5, 2021·35 cites·16 claims
- 1998US11110156B2Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigenCUREVAC AG·Filed 2018·Granted Sep 7, 2021·28 cites·18 claims
- 2098US11034729B2Respiratory syncytial virus (RSV) vaccineCUREVAC AG·Filed 2018·Granted Jun 15, 2021·35 cites·20 claims
- 2198US10912826B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2020·Granted Feb 9, 2021·45 cites·21 claims
- 2298US10898589B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2018·Granted Jan 26, 2021·28 cites·16 claims
- 2398US10898584B2Modified RNA with decreased immunostimulatory propertiesCUREVAC AG·Filed 2016·Granted Jan 26, 2021·30 cites·17 claims
- 2498US10799577B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2018·Granted Oct 13, 2020·28 cites·22 claims
- 2598US10751424B2Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acidsCUREVAC AG·Filed 2018·Granted Aug 25, 2020·29 cites·17 claims
- 2698US10729761B2Vaccination in newborns and infantsCUREVAC AG·Filed 2019·Granted Aug 4, 2020·30 cites·20 claims
- 2798US10729654B2Dry powder composition comprising long-chain RNACUREVAC AG·Filed 2016·Granted Aug 4, 2020·36 cites·15 claims
- 2898US10682406B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2018·Granted Jun 16, 2020·29 cites·22 claims
- 2998US10682426B2Rabies vaccineCUREVAC AG·Filed 2016·Granted Jun 16, 2020·30 cites·17 claims
- 3098US10596252B2Vaccination in newborns and infantsCUREVAC AG·Filed 2018·Granted Mar 24, 2020·30 cites·19 claims
- 3198US10588959B2Combination vaccineCUREVAC AG·Filed 2016·Granted Mar 17, 2020·30 cites·25 claims
- 3298US10568972B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Feb 25, 2020·35 cites·23 claims
- 3398US10293058B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2016·Granted May 21, 2019·50 cites·16 claims
- 3498US10172935B2Vaccination in newborns and infantsCUREVAC AG·Filed 2017·Granted Jan 8, 2019·33 cites·16 claims
- 3598US10166283B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCUREVAC AG·Filed 2017·Granted Jan 1, 2019·37 cites·19 claims
- 3698US10111968B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2016·Granted Oct 30, 2018·39 cites·20 claims
- 3798US10047375B2Artificial nucleic acid moleculesCUREVAC AG·Filed 2016·Granted Aug 14, 2018·32 cites·18 claims
- 3898US9839697B2Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCUREVAC AG·Filed 2015·Granted Dec 12, 2017·39 cites·20 claims
- 3998US9688729B2Respiratory syncytial virus (RSV) vaccineCUREVAC AG·Filed 2016·Granted Jun 27, 2017·66 cites·21 claims
- 4097US11534405B2Dry powder composition comprising long-chain RNACUREVAC AG·Filed 2020·Granted Dec 27, 2022·11 cites·18 claims
- 4197US11471525B2Coronavirus vaccineCUREVAC AG·Filed 2021·Granted Oct 18, 2022·18 cites·29 claims
- 4297US11369691B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Jun 28, 2022·11 cites·19 claims
- 4397US11241493B2Coronavirus vaccineCUREVAC AG·Filed 2021·Granted Feb 8, 2022·54 cites·27 claims
- 4497US11149278B2Artificial nucleic acid molecules for improved protein expressionCUREVAC AG·Filed 2015·Granted Oct 19, 2021·31 cites·20 claims
- 4597US11110157B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2019·Granted Sep 7, 2021·28 cites·13 claims
- 4697US11110166B2Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvantCUREVAC AG·Filed 2019·Granted Sep 7, 2021·32 cites·20 claims
- 4797US10918740B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2018·Granted Feb 16, 2021·38 cites·19 claims
- 4897US10799602B2Method for increasing expression of RNA-encoded proteinsCUREVAC AG·Filed 2019·Granted Oct 13, 2020·36 cites·20 claims
- 4997US10653799B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded proteinCUREVAC AG·Filed 2017·Granted May 19, 2020·28 cites·20 claims
- 5097US10610605B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic proteinCUREVAC AG·Filed 2018·Granted Apr 7, 2020·28 cites·17 claims
Showing the top 50 of 195 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →